Therapy News and Research

RSS

Fox Chase Cancer Center announces first-in-human bi-specific HER2/HER3 pathway targeting antibody

Patients with HER2-positive cancers can have dramatic responses to HER2-targeted drugs but eventually develop resistance to the agents. With that problem in mind, Fox Chase Cancer Center researchers are testing a novel type of antibody called MM-111 in patients with HER2-positive disease who have progressed on standard therapy.

5 Jun 2010

Nasendoscopies help predict response to OAT in sleep apnea patients

According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, nasendoscopy may help dentists predict oral appliance therapy success in sleep apnea patients. Nasendoscopy involves a flexible endoscope being inserted through the nasal cavity. The tip of the scope is placed at the level of the velopharynx and oro-/hypopharynx.

5 Jun 2010

Teva reports encouraging data from study assessing new lower-volume injection of Copaxone at 24th CMSC

Teva Pharmaceutical Industries Ltd. today announced positive results from a study assessing a new lower-volume injection of Copaxone® (glatiramer acetate) containing the currently approved dose in half the injection volume.

5 Jun 2010

Prismatic eyeglass lenses reduce symptoms associated with TBI, vertical heterophoria: Study

A recent retrospective study by four Michigan physicians shows strong evidence that symptoms of headache, dizziness and anxiety in some patients with traumatic brain injury potentially could be alleviated or even eliminated with specialized eyeglass lenses containing prisms.

5 Jun 2010

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas MD Anderson Cancer Center.

5 Jun 2010

Hip strengthening regimen proves effective at reducing PFP in female runners: Study

A twice weekly hip strengthening regimen performed for six weeks proved surprisingly effective at reducing -- and in some cases eliminating -- knee pain referred to as patellofemoral pain in female runners.

5 Jun 2010

John Theurer Cancer Center to showcase treatment advancements for cancer at ASCO 2010

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings that will be presented at the American Society of Clinical Oncology annual meeting taking place June 4 - 8, 2010 in Chicago. Research highlights include a comparison of first-line treatments for an aggressive form of lymphoma, the efficacy and safety of a new genetically engineered cancer therapy, and the value of a commonly used tool for staging lymphoma.

5 Jun 2010

Acute neurological toxicity associated with chronic neurological toxicity in patients with high-grade gliomas

Patients with high-grade gliomas who experience acute (early) neurological toxicity during their treatment were more likely to experience chronic (late) neurological toxicity and shortened overall survival, according to researchers from the Kimmel Cancer Center at Jefferson. The study will be presented at the 2010 ASCO Annual Meeting in Chicago (Abstract #2037).

5 Jun 2010

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

5 Jun 2010

Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 2010

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, reported final results from the Phase 2, open-label ENCORE 303 trial in post-menopausal women with advanced, estrogen receptor positive breast cancer who were progressing on aromatase inhibitor therapy.

5 Jun 2010

Encore Path signs license agreement for UMB technology that helps stroke patients redevelop natural gait

The University of Maryland, Baltimore's Office of Research and Development announced that Encore Path, Inc. of Baltimore signed an exclusive worldwide license agreement for a device technology invented jointly by researchers at the University of Maryland, Baltimore and the University of Maryland Baltimore County that helps stroke patients retrain their bodies to walk.

5 Jun 2010

PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

Pacific Edge (PEB), a New Zealand-based biomedical company, today announced the successful completion of the European clinical trial for their prognostic gene signature for colorectal cancer. The clinical trial results showed a successful outcome that enables patients diagnosed with UICC stage II or UICC stage III colorectal cancer and with a high risk of disease progression to be identified and treated more appropriately.

5 Jun 2010

VA partners with National Institutes of Health to research on Parkinson's disease

Veterans and others with Parkinson's disease who undergo deep brain stimulation may benefit from research co-sponsored by the Department of Veterans Affairs and published recently in the prestigious New England Journal of Medicine.

5 Jun 2010

Walter Reed Army Medical Center to treat pain patients with CTT's Calmare Pain Therapy Treatment

Competitive Technologies, Inc. announced today that the Walter Reed Army Medical Center in Washington, D.C., has joined the growing list of organizations that will treat pain patients with CTT's Calmare Pain Therapy Treatment, as authorized by the Surgeon General of the U.S. Army and Commanding General of the U.S. Army Medical Command.

5 Jun 2010

Biomet Biologics initiates enrollment in MarrowStim P.A.D. Kit IDE trial for critical limb ischemia

Biomet, a global leader in the manufacture of orthopedic and biotechnology products, announced today that its subsidiary, Biomet Biologics, has enrolled the first subject into its multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial for critical limb ischemia (CLI).

5 Jun 2010

Montefiore-Einstein announces Abdominal Organ Transplant Symposium on June 10, 2010

The Montefiore-Einstein Abdominal Organ Transplantation Service will hold an Abdominal Organ Transplant Symposium on Thursday, June 10, 2010 from 7:30 am - 4:30 pm at the Moses Division of Montefiore Medical Center on Gun Hill Road in the Bronx, NY.

4 Jun 2010

Roche's new dual-PCR target HIV-1 viral load test receives FDA approval

Roche Molecular Diagnostics announced today that the Food and Drug Administration (FDA) approved its new dual-PCR target HIV-1 viral load test to quantify the amount of virus in a patient's blood. The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 is the first quantitative viral load test to amplify and detect two separate regions of a target genome and offers a fully automated and reliable solution for physicians to make informed treatment decisions for HIV-1 patients undergoing antiretroviral therapy.

4 Jun 2010

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.

4 Jun 2010

Life Technologies partners to create Genomic Cancer Care Alliance

Life Technologies Corporation today announced the creation of the Genomic Cancer Care Alliance to help people battling cancer gain access to treatment options found through analysis of their genomic information. Founding partners include Fox Chase Cancer Center, Scripps Genomic Medicine, and the Translational Genomics Research Institute (TGen). The announcement came during the Consumer Genetics Conference being held June 2-4 in Boston.

4 Jun 2010

ASTRO to honor David Larson and William McBride with prestigious Gold Medal award

David Larson, M.D., Ph.D., FASTRO, and William McBride, D.Sc., Ph.D., have been chosen to receive the American Society for Radiation Oncology's most prestigious award, the Gold Medal. They will be presented with this honor at the Awards Ceremony during ASTRO's 52nd Annual Meeting, taking place October 31 to November 4, 2010, in San Diego.

4 Jun 2010

Therapy News and Research

Fox Chase Cancer Center announces first-in-human bi-specific HER2/HER3 pathway targeting antibody

Nasendoscopies help predict response to OAT in sleep apnea patients

Teva reports encouraging data from study assessing new lower-volume injection of Copaxone at 24th CMSC

Prismatic eyeglass lenses reduce symptoms associated with TBI, vertical heterophoria: Study

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

Hip strengthening regimen proves effective at reducing PFP in female runners: Study

John Theurer Cancer Center to showcase treatment advancements for cancer at ASCO 2010

Acute neurological toxicity associated with chronic neurological toxicity in patients with high-grade gliomas

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 2010

Encore Path signs license agreement for UMB technology that helps stroke patients redevelop natural gait

PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

VA partners with National Institutes of Health to research on Parkinson's disease

Walter Reed Army Medical Center to treat pain patients with CTT's Calmare Pain Therapy Treatment

Biomet Biologics initiates enrollment in MarrowStim P.A.D. Kit IDE trial for critical limb ischemia

Montefiore-Einstein announces Abdominal Organ Transplant Symposium on June 10, 2010

Roche's new dual-PCR target HIV-1 viral load test receives FDA approval

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Life Technologies partners to create Genomic Cancer Care Alliance

ASTRO to honor David Larson and William McBride with prestigious Gold Medal award

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News